Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy

Cancer Research

Volumn 73, Issue 8, 2013, Pages 2598-2607

  Lim, Seon Ah ^a   Kim, Tae Jin ^a,e   Lee, Jung Eun ^a,d   Sonn, Chung Hee ^a   Kim, Kwanghee ^a   Kim, Jiyoung ^a   Choi, Jong Gwon ^b   Choi, Il Kyu ^c   Yun, Chae Ok ^c   Kim, Jae Hong ^d   Yee, Cassian ^f,g   Kumar, Vinay ^e   Lee, Kyung Mi ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Hanyang University   (South Korea)

^d Korea University   (South Korea)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; FC RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELL EXPANSION; CELL GROWTH; COCULTURE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; EX VIVO STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IRRADIATION; LEUKEMIA CELL LINE; LIGAND BINDING; LYMPHOCYTE TRANSFORMATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION;

B-LYMPHOCYTES; CELL COMMUNICATION; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEEDER CELLS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LIGANDS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84876887378     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2893     Document Type: Article

References (37)

1. Caligiuri MA. Human natural killer cells. Blood 2008;112:461-9.
2. Ljunggren H-G, Malmberg K-J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007;7:329-39.
3. Moretta L, Moretta A. Unravelling natural killer cell function: Triggering and inhibitory human NK receptors. EMBO J 2004;23:255-9.
4. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295: 2097-100.
5. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: Evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009;113:3119-29.
6. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011;13:98-107.
7. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial. Cytotherapy 2008;10: 625-32.
8. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004;24:1861-71.
9. deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W, et al. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother 2000;23:154-60.
10. Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: A clinical phase i trial. Clin Cancer Res 2004;10:3699-707.
11. Watzl C, Long EO. Exposing tumor cells to killer cell attack. Nat Med 2000;6:867-8.
12. Pardoll DM. Stress, NK receptors, and immune surveillance. Science 2001;294:534-6.
13. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: Current insights and future prospects. J Intern Med 2009;266:154-81.
14. Cho D, Campana D. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med 2009;29:89-96.
15. Yee C. Adoptive therapy using antigen-specific T-cell clones. Cancer J 2010;16:367-73.
16. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990;128:189-201.
17. Kim TJ, KimN, Kang HJ, Kim EO, Kim ST, Ahn HS, et al. FK506 causes cellular and functional defects in human natural killer cells. J Leukoc Biol 2010;88:1089-97.
18. Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine 2004;28:109-23.
19. Lee KM, Forman JP, McNerney ME, Stepp S, Kuppireddi S, Guzior D, et al. Requirement of homotypic NK-cell interactions through 2B4 (CD244)/CD48 in the generation of NK effector functions. Blood 2006;107:3181-8.
20. Sutlu T, Stellan B, Gilljam M, Quezada HC, Nahi H, Gahrton G, et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 2010;12:1044-55.
21. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A 1999;96:5640-4.
22. Gao N, Jennings P, Yuan D. Requirements for the natural killer cellmediated induction of IgG1 and IgG2a expression in B lymphocytes. Int Immunol 2008;20:645-57.
23. Carbone E, Ruggiero G, Terrazzano G, Palomba C, Manzo C, Fontana S, et al. A new mechanism of NK cell cytotoxicity activation: The CD40-CD40 ligand interaction. J Exp Med 1997;185:2053-60.
24. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 1984;160:1147-69.
25. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180:1395-403.
26. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009;69:4010-7.
27. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008;111:3155-62.
28. Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG, et al. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol 2001;62:1092-8.
29. Luhm J, Brand JM, Koritke P, Hoppner M, Kirchner H, Frohn C. Largescale generation of natural killer lymphocytes for clinical application. J Hematother Stem Cell Res 2002;11:651-7.
30. Perussia B, Ramoni C, Anegon I, Cuturi MC, Faust J, Trinchieri G. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul 1987;6:171-88.
31. Harada H, Watanabe S, Saijo K, Ishiwata I, Ohno T. A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells. Exp Hematol 2004;32:614-21.
32. Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood 1992;80: 2221-9.
33. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106:376-83.
34. Phillips JH, Lanier LL. A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562. J Exp Med 1985;161:1464-82.
35. Gong W, Xiao W, Hu M, Weng X, Qian L, Pan X, et al. Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15. Tissue Antigens 2010;76:467-75.
36. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005;105:3615-22.
37. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 2012;7: E30264.